Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for November 2008
November 3, 2008
- Over 60 Million U.S. Adults Engaging in Health 2.0
- Tweens and Teens Double Use of Diabetes Drugs
- Daiichi Sankyo Acquires Merck Serono's Cardio-Metabolism Sales Force and Products in Turkey
- Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
- Avigen Announces Restructuring and Strategic Direction
November 4, 2008
- John Patterson to Retire from AstraZeneca
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Replidyne and Cardiovascular Systems Sign Merger Agreement
- Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra and Launches Immediately
November 5, 2008
- Westaim Terminates Reorganization Agreement and Cancels Shareholders' Meeting
- Drug Companies Gave Vermont Health Care Providers Gifts Worth $4.9 Million Over Two Years
- Grassley Calls on FDA Leaders to Address Mismanagement of FDA Employee Pay and Benefits
- Hospira Reports Third-Quarter 2008 Results
- ImClone Systems Announces Expiration of Hart-Scott-Rodino Waiting Period
- Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
- Urigen Outlines Operating Plans
November 6, 2008
- FDA Reports Nationwide Recall of Mislabeled ReliOn Insulin Syringes
- King Pharmaceuticals Reports Third-Quarter 2008 Financial Results
- Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)
- Teva Reports Third Quarter 2008 Results
- Devgen announces the intention to close its pharma division and to fully focus on the development of its agro business
- Sanofi-aventis to Discontinue all Clinical Trials with rimonabant
- Teva Updates 2008 Financial Outlook
November 7, 2008
- FDA Seizes Contaminated Heparin from a Cincinnati Manufacturer
- Express Scripts Warns of Potential Large Data Breach Tied to Threat
- Novo Nordisk Invests Close to 400 Million US Dollars in New Insulin Production Plant in China
- Amgen Positioned to Deliver Attractive Growth Over Next Five Years
- CHI Congratulates Congressional Election Winners
November 10, 2008
- Sanofi Pasteur First International Vaccine Company to Enter Japan With Pediatric Vaccine ActHIB (Haemophilus Influenzae Type b Vaccine) Available in Japan on December 19, 2008
- Biovest International Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize its Drugs and Technologies
November 11, 2008
- Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
- ASI Announces Results of Advertising Specialties Impression Study
- Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
- New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug
November 12, 2008
- Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
- GeneNews Restructures Operations
- FDA Approves 30-Minute Onset of Action for Focalin XR
- Express Scripts Reports New Threats Tied to Data Security Breach
- GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
November 13, 2008
- FDA Updates the Early Communication about the Ongoing Safety Review of Bisphosphonates
- FDA Warns Public of Extortion Scam by FDA Impersonators
- Pharmaceutical Industry Needs To Speed Up Transformation To Meet Changing Market Dynamics, According To Ernst & Young Report
- FDA MedWatch- Bisphosphonates-Update To The Early Communication Issued Regarding Atrial Fibrillation With Bisphosphonates
- FDA Warns Public of Extortion Scam by FDA Impersonators
- Public Statement On Exubera (Insulin Human) Withdrawal Of The Marketing Authorisation In The European Union
- Novo Nordisk Launches Levemir Satisfaction Guarantee Program
November 14, 2008
- Actavis Comments on Filing of DOJ Complaint
- Pfizer Launches Global Regenerative Medicine Research Unit
- Valeant Pharmaceuticals Acquires DermaTech
- Senate Finance Chairman Baucus Unveils Blueprint for Comprehensive Health Care Reform
- The U.S. Remains Preferred Market for Launching New Products
- Javelin Pharmaceuticals Announces 15 Percent Reduction in Workforce
November 17, 2008
- FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
- Roche, Merck Serono and Abbott Join Forces in Biotechnology Cluster Rhine-Neckar (BioRN)
- Out-of-Pocket Costs Grow in Medicare Part D
- FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
- Solvay Pharmaceuticals Discontinues R&D Activities of its Anti-Obesity Compound SLV319
- Progenics Announces Wyeth Has Received Relistor Approval in Australia
- BioSante Pharmaceuticals Announces Receipt of NIH Grant for Inhaled Interferon
- Mortara Instrument Announces Extension of ECG Warehouse CRADA With US FDA
November 18, 2008
- ImClone Systems Announces Clearance of Tender Offer by German FederalCartel Office
- Genentech Issues Dear Healthcare Provider Letter Regarding a2nd Case of PML in a Raptiva Patient
- ACI’s FDA Boot Camp is the industry standard in providing non-regulatory professionals with the regulatory foundation critical to success
- Manhattan Research Releases Report on the Future of Physician Customer Service Portals
- AstraZeneca Appoints Rich Fante as President of its U.S. Business
- I'm Sticking With My Brand: Loyal Customers Perceive Competitor Ads Differently
- Study Finds Cost of Diabetes in the United States Exceeds $217 Billion
- Sanofi-Aventis Pharma S.A. Withdraws Its Application for an Extension of Indication for Taxotere and Docetaxel Winthrop (docetaxel)
- Public Statement on Forcaltonin - Withdrawal of the Marketing Authorisation in the European Union
- Telephone Counseling May Improve Effectiveness of Varenicline (Chantix), According to Free & Clear Study
- ACP Guideline Finds No Substantial Differences Among “Second-Generation” Antidepressants
November 19, 2008
- ADHD Medications Do Not Cause Genetic Damage In Children
- Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline
- Barr Announces Agreements on Nasacort AQ, Allegra D-12 and Allegra Patent Challenges
- Teva Receives First U.S. Approval for Generic Pulmicort Respules;Commences Commercial Launch
- Widely-Used Cancer Drug Associated With Significantly Increased Risk of Blood Clots
- Prescription Project Welcomes U.S. Appeals Court Ruling in “Data-Mining” Case
- Nevada Attorney General Cortez Masto Files Suit Against Hormone Therapy Drug Manufacturers
- IMS v. Ayotte - Physician Privacy Law Upheld as Constitutional by First Circuit
- Media Statement re: New Hampshire's Decision to Overturn a New Hampshire U.S. District Court Ruling that Struck Down the State’s Law Banning the Commercial Use of Prescriber-Identifiable Data
- AstraZeneca Enters Agreement for Authorized Generic Pulmicort Respules
- WebMD and Marketing Technology Solutions Terminate Merger Agreement
- Ambrilia Initiates Plan Aiming to Significantly Reduce its Operations in France
- Orion to Renew Operational Model of Pharmaceutical R&D. Negotiation Proposal on Reduction of up to 300 Employees in Finland
November 20, 2008
- Pfizer Withdraws Application to Switch Viagra to Non-PrescriptionStatus in Europe
- BIO Congratulates Former Senator Tom Daschle on His Nomination toServe as HHS Secretary
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- FDA Advisory Committee Provides Opinion on Oritavancin for theTreatment of Complicated Skin and Skin Structure Infections
- AstraZeneca to Realign Supply Chain to Improve Productivity and Move Closer to Customers
- Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
- AstraZeneca Granted Temporary Restraining Order in Pulmicort Respules Patent Litigation
- New Jersey Jury Awards $12.9 Million to Three Patients Whose Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
- Cervarix, GSK’s Cervical Cancer Vaccine, Wins Tender for Dutch National Immunisation Programme
- FDA Sends Warning Letter to Shionogi Over Cedax Direct Mailers
- European Medicines Agency Recommends the Suspension of the Marketing Authorisation of Ionsys (fentanyl hydrochloride)
- FDA Sends Letter to Protherics Over Voraxaze Web Material
- Internet Advertising Revenues in Q3 ’08 at Nearly $5.9 Billion
November 21, 2008
- Vical Announces Strategic Restructuring and Staff Reduction
- SurModics Announces Changes to Its Organizational Structure and Cost-Cutting Initiatives
- Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension
- CombinatoRx Concentrates on Core Strengths
- Lilly Completes Cash Tender Offer for ImClone Systems
- Nplate (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
- MINRAD International, Inc. Announces Reduction in Workforce
- CHMP Posts 12 Opinions
- Physicians Anticipate Higher Prescribing Based on JUPITER Study
- Barr Shareholders Approve Pending Teva Acquisition
- New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes
November 24, 2008
- Labopharm's NDA for Novel Trazodone Formulation Accepted for Review by FDA
- King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
- Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
- PhRMA Statement on New National Advertising Campaign
- FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor (Doxepin) by up to Three Months
- XDx Announces Strategic Restructuring
- Lilly Completes Acquisition of ImClone Systems
- Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
- Genzyme Seeks U.S. Approval for Clolar to Treat Adult AML
November 25, 2008
- AstraZeneca Provides Update on Agreement with Abraxis Biosciences for Co-Promotion of Abraxane in the US
- Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
- Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
- Antitrust: European Commission Confirms Unannounced Inspections at Pharmaceutical Companies
- Anika Therapeutics Terminates Contract with U.S. Distribution Partner for ELEVESS
- Bayer Healthcare to Pay U.S. $97.5 Million to Settle Allegations of Paying Kickbacks to Diabetic Suppliers
- Bayer Healthcare llc Reaches Settlement with U.S. Department of Justice on Investigation into former Diabetes Care Marketing Programs
November 26, 2008
- FDA Sends Warning Letter to Actelion Over Tracleer Flash Card
- Use Of Inhaled Corticosteroids For Copd Does Not Appear To Improve Survival, But May Increase Risk For Pneumonia
- FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
- Pfizer's Novel HIV/AIDS Treatment Selzentry Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients
- Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
- Growth hormone not beneficial for ALS
